Use the Back button in your browser to see the other results of your search or to select another record.
Detailed Search Results
| Sportizumab -- multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: a randomized controlled trial [with consumer summary] |
| Proschinger S, Belen S, Adammek F, Schlagheck ML, Rademacher A, Schenk A, Warnke C, Bloch W, Zimmer P |
| Brain, Behavior, and Immunity 2024 Feb;124:397-408 |
| clinical trial |
| 6/10 [Eligibility criteria: No; Random allocation: Yes; Concealed allocation: Yes; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: No; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed* |
|
Copyright release for this abstract has not been granted.
|
The database was last updated on 3 October 2025 (this includes records added or amended since 1 September 2025). The next update is planned for 3 November 2025. The total number of records on the database is 66,367.